Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

FLEXION THERAPEUTICS INC (FLXN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
26.49(c) 26.36(c) 25.09(c) 24.73(c) 24.5(c) Last
765 062 450 941 662 152 754 696 622 272 Volume
+4.37% -0.49% -4.82% -1.43% -0.93% Change
More quotes
Financials (USD)
Sales 2018 26,9 M
EBIT 2018 -183 M
Net income 2018 -192 M
Finance 2018 195 M
Yield 2018 -
Sales 2019 128 M
EBIT 2019 -109 M
Net income 2019 -117 M
Finance 2019 52,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 27,3x
EV / Sales2019 6,88x
Capitalization 930 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
04/19FLEXION THERAPEUTICS : Announces Publication of Results from Pivotal Phase 3 Stu..
AQ
04/18FLEXION THERAPEUTICS : Announces Publication of Results from Pivotal Phase 3 Stu..
AQ
04/06FLEXION THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(..
AQ
04/02FLEXION THERAPEUTICS INC : Other Events (form 8-K)
AQ
03/19Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare..
GL
03/08FLEXION THERAPEUTICS : reports 4Q loss
AQ
03/08FLEXION THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
03/08FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition, Financ..
AQ
03/08Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Resu..
GL
03/08FLEXION THERAPEUTICS INC : Flexion Therapeutics, Inc. to Host Earnings Call
AC
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04:03a$FLXN - Zacks: Brokerages Anticipate Flexion Therapeutics #FLXN Will Post Ear.. 
04:01aFlexion Therapeutics $FLXN Expected to Announce Quarterly Sales of $2.40 Mill.. 
04/21Zacks: Brokerages Expect Flexion Therapeutics $FLXN to Post -$1.35 Earnings P.. 
04/19Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 St.. 
04/19$FLXN: Flexion Therapeutics results from pivotal Phase 3 Study of ZILRETTA (t.. 
More tweets
Qtime:53
News from SeekingAlpha
04/09Novartis takeout of AveXis stokes buying in gene therapy players 
03/15Flexion Therapeutics (FLXN) Presents At 38th Annual Cowen And Company Healthc.. 
03/09Flexion Therapeutics (FLXN) CEO Mike Clayman on Q4 2017 Results - Earnings Ca.. 
03/08Flexion Therapeutics misses by $0.35, misses on revenue 
03/02Key events next week - healthcare 
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 38,6 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Scott D. Kelley Chief Medical Officer
Yamo Deniz Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC-1.24%930
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998